KALV - KalVista Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5291.25M
Enterprise Value 3187.37M
Trailing P/E N/A
Forward P/E 1-7.68
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)18.06
Price/Book (mrq)2.99
Enterprise Value/Revenue 311.62
Enterprise Value/EBITDA 6-6.36

Trading Information

Stock Price History

Beta (3Y Monthly) 1.54
52-Week Change 39.74%
S&P500 52-Week Change 31.52%
52 Week High 334.92
52 Week Low 314.50
50-Day Moving Average 317.15
200-Day Moving Average 321.82

Share Statistics

Avg Vol (3 month) 3178.65k
Avg Vol (10 day) 368.76k
Shares Outstanding 5N/A
Float 9.31M
% Held by Insiders 110.43%
% Held by Institutions 178.57%
Shares Short (Jul 31, 2019) 4934.91k
Short Ratio (Jul 31, 2019) 45.93
Short % of Float (Jul 31, 2019) 414.32%
Short % of Shares Outstanding (Jul 31, 2019) 45.38%
Shares Short (prior month Jun 28, 2019) 4752.66k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 214/1
Last Split Date 3Nov 22, 2016

Financial Highlights

Fiscal Year

Fiscal Year Ends Apr 30, 2019
Most Recent Quarter (mrq)Apr 30, 2019

Profitability

Profit Margin -129.08%
Operating Margin (ttm)-184.91%

Management Effectiveness

Return on Assets (ttm)-20.76%
Return on Equity (ttm)-33.58%

Income Statement

Revenue (ttm)16.13M
Revenue Per Share (ttm)1.07
Quarterly Revenue Growth (yoy)-39.50%
Gross Profit (ttm)-18.89M
EBITDA -29.44M
Net Income Avi to Common (ttm)-20.82M
Diluted EPS (ttm)-1.38
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)100.81M
Total Cash Per Share (mrq)5.8
Total Debt (mrq)54k
Total Debt/Equity (mrq)0.06
Current Ratio (mrq)6.40
Book Value Per Share (mrq)5.60

Cash Flow Statement

Operating Cash Flow (ttm)-36.37M
Levered Free Cash Flow (ttm)-27.78M